David Allard
Centre Hospitalier de l’Université de Montréal · 54 works · 5,424 citations · h-index 21
Top works
- The adenosine pathway in immuno-oncology
- CD73–Adenosine: A Next-Generation Target in Immuno-Oncology
- Targeting A2 adenosine receptors in cancer
- Targeting the CD73-adenosine axis in immuno-oncology
- On the mechanism of anti-CD39 immune checkpoint therapy
- CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy
- DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells
- Targeting the adenosine pathway for cancer immunotherapy
- CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
- PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors
- Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis
- High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
- The CD73 immune checkpoint promotes tumor cell metabolic fitness
- Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies
- Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
- Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis
- Publisher Correction: The adenosine pathway in immuno-oncology
- CD73 Promotes Chronic Lymphocytic Leukemia
- CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination
- The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer